Literature DB >> 12969141

C1q nephropathy: a variant of focal segmental glomerulosclerosis.

Glen S Markowitz1, Joshua A Schwimmer, M Barry Stokes, Samih Nasr, Robert L Seigle, Anthony M Valeri, Vivette D D'Agati.   

Abstract

BACKGROUND: C1q nephropathy is a poorly understood and controversial entity with distinctive immunopathologic features. In order to better define the clinical-pathologic spectrum, we report the largest single-center series.
METHODS: Nineteen biopsies with C1q nephropathy were identified from among 8909 native kidney biopsies received from 1994 to 2002 (0.21%). Defining criteria included (1). dominant or co-dominant immunofluorescence staining for C1q, (2). mesangial electron dense deposits, and (3). no clinical or serologic evidence of systemic lupus erythematosus (SLE).
RESULTS: The 19 patients were predominantly African American (73.7%), female (73.7%), young adults and children (range, 3 to 42 years; mean, 24.2 years). Presentation included nephrotic range proteinuria (78.9%), nephrotic syndrome (50%), renal insufficiency (27.8%), and hematuria (22.2%). No patient had hypocomplementemia or evidence of underlying autoimmune or infectious disease. Renal biopsy revealed focal segmental glomerulosclerosis (FSGS) in 17 (including six collapsing and two cellular) and minimal-change disease (MCD) in two. All biopsies displayed co-deposits of immunoglobulin G (IgG), with more variable IgM (84.2%), IgA (31.6%), and C3 (52.6%). Foot process effacement varied from 20% to 100% (mean, 51%). Twelve of 16 patients with available follow-up received immunosuppressive therapy. One patient had complete remission of proteinuria and six had partial remission. Four patients with FSGS pattern had progressive renal insufficiency, including two who reached end-stage renal disease (ESRD). Median time from biopsy to ESRD was 81 months. On multivariate analysis, the best correlate of renal insufficiency at biopsy and at follow-up was the degree of tubular atrophy and interstitial fibrosis (P = 0.0495 and 0.0341, respectively).
CONCLUSION: C1q nephropathy falls within the clinical-pathologic spectrum of MCD/FSGS. Although further studies are needed to determine the pathomechanism of C1q deposition, we hypothesize that it may be a non-specific marker of increased mesangial trafficking in the setting of glomerular proteinuria.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12969141     DOI: 10.1046/j.1523-1755.2003.00218.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  35 in total

1.  C1q nephropathy with asymptomatic urine abnormalities.

Authors:  Masashi Nishida; Hidekazu Kawakatsu; Yasuko Okumura; Kenji Hamaoka
Journal:  Pediatr Nephrol       Date:  2005-08-16       Impact factor: 3.714

2.  Positive C1q staining associated with poor renal outcome in membranoproliferative glomerulonephritis.

Authors:  Takashi Takei; Mitsuyo Itabashi; Takahito Moriyama; Ari Shimizu; Yuki Tsuruta; Ayami Ochi; Kayu Nakayama; Chihiro Iwasaki; Keiko Uchida; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2012-07-21       Impact factor: 2.801

3.  Is collapsing C1q nephropathy another MYH9-associated kidney disease? A case report.

Authors:  Amber M Reeves-Daniel; Samy S Iskandar; Donald W Bowden; Meredith A Bostrom; Pamela J Hicks; Mary E Comeau; Carl D Langefeld; Barry I Freedman
Journal:  Am J Kidney Dis       Date:  2010-01-29       Impact factor: 8.860

4.  C1q nephropathy in a child presenting with recurrent gross hematuria.

Authors:  Luke Taggart; Alexis Harris; Samir El-Dahr; Franca Iorember
Journal:  Pediatr Nephrol       Date:  2010-01       Impact factor: 3.714

5.  C1q nephropathy in children: clinical characteristics and outcome.

Authors:  Vindya N Gunasekara; Neil J Sebire; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2013-12-11       Impact factor: 3.714

6.  C1q nephropathy in two young sisters.

Authors:  Jameela A Kari; Sawsan M Jalalah
Journal:  Pediatr Nephrol       Date:  2007-10-21       Impact factor: 3.714

7.  Rituximab treatment of collapsing C1q glomerulopathy: clinical and histopathological evolution.

Authors:  Martin Bitzan; Jodie D Ouahed; Preetha Krishnamoorthy; Chantal Bernard
Journal:  Pediatr Nephrol       Date:  2008-03-20       Impact factor: 3.714

8.  C1q nephropathy and minimal change nephrotic syndrome.

Authors:  Craig S Wong; Christopher A Fink; Jane Baechle; Alexis A Harris; Amy O Staples; John R Brandt
Journal:  Pediatr Nephrol       Date:  2008-12-11       Impact factor: 3.714

9.  A single-center study of C1q nephropathy in children.

Authors:  Isabel Roberti; Noosha Baqi; Shefali Vyas; Dae Un Kim
Journal:  Pediatr Nephrol       Date:  2008-08-08       Impact factor: 3.714

Review 10.  Current status and issues of C1q nephropathy.

Authors:  Akiko Mii; Akira Shimizu; Yukinari Masuda; Emiko Fujita; Kaoru Aki; Masamichi Ishizaki; Shigeru Sato; Adam Griesemer; Yuh Fukuda
Journal:  Clin Exp Nephrol       Date:  2009-04-17       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.